The drugmaker is shuttering a facility that’s been open 36 years and, more recently, has been used to make its Pravachol cholesterol pill, the Abilify schizhophrenia treatment and Glucophage diabetes med. The closing will occur in stages and be completed by the end of next year, a Bristol spokeswoman told the Associated Press.

One of the reasons cited for the closing is reduced demand for the meds, although Abilify production will be shifted elsewhere. Bristol-Myers operates manufacturing facilities in three other Puerto Rican cities. The drugmaker, for instance, recently remodeled its plant in the northern city of Manati, investing $220 million in two years, according to Boris Jaskille, executive director of Puerto Rico’s Industrial Development Company. “They envision that Manati will be the center of production for biological medications on a global level,” he says.

Interestingly, Bristol-Myers didn’t issue any news release or post one on its website, which is typical of companies that are in the process of eliminating numerous jobs. Typically, the reason give for the lack of disclosure is that some information isn’t material to investors. As a practical matter, though, companies prefer not to draw attention to such bad news.

This is, by the way, the second recent announcement of a plant closing on Puerto Rico, which has long been home to numerous pharma manufacturing facilities. Last week, Glaxo announced plans to close a plant because of declining sales of diabetes treatments and growing competition from generic medication. The move will eliminate 650 of 900 jobs.